Prior to co-founding Medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He was formerly on the board of directors of Versartis (Nasdaq: VSAR) and is currently involved with Acutus and Levicept among others.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.
Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University.